• 1
    Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004; 13: 279287.
  • 2
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 49904997.
  • 3
    Moreno C, Villamor N, Colomer D, et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 34333438.
  • 4
    Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005; 105: 4953.
  • 5
    Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005; 11: 41764181.
  • 6
    Rai K, Moore JO, Boyd TE, et al. Phase 3 randomized trial of fludarabine/cyclophos-phamide chemotherapy with or without oblimersen sodium (Bcl-2 antisense; Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2004; 104: 100a.
  • 7
    Frankel AE, Kreitman RJ. CLL immunotoxins. Leuk Res. 2005; 29: 985986.
  • 8
    Williams DP, Snider CE, Strom TB, Murphy JR. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem. 1990; 265: 1188511889.
  • 9
    Bamborough P, Hedgecock CJ, Richards WG. The interleukin-2 and interleukin-4 receptors studied by molecular modeling. Structure. 1994; 2: 839851.
  • 10
    Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical application. Cytokine. 2004; 28: 109123.
  • 11
    Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res. 1996; 56: 25902595.
  • 12
    LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998; 91: 399405.
  • 13
    Olsen E, Duvic M, Frankel AE, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19: 376388.
  • 14
    Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma. 2001; 1: 298302.
  • 15
    Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004; 22: 40954102.
  • 16
    Tsilivakos V, Tsapis A, Kokolyris S, Iliakis P, Perraki M, Georgoulias V. Characterization of interleukin 2 receptors on B-cell chronic lymphocytic leukemia cells. Leukemia. 1994; 8: 15711578.
  • 17
    Frankel AE, Fleming DR, Hall PD, et al. A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003; 9: 35553561.
  • 18
    Morgan SJ, Seymour JF, Prince HM, Westerman DA, Wolf MM. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia including cases with chromosome 17p deletion and without detectable CD25 expression. Clin Cancer Res. 2004; 10: 35723575.
  • 19
    Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002; 94: 20332039.
  • 20
    Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005; 106: 20182025. Epub 2005 May 24.
  • 21
    Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942949.
  • 22
    Scheffold A, Huhn J, Hofer T. Regulation of CD24+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol. 2005; 35: 13361341.